Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT06284486
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- NCT06284486 ↗
- Recruiting
- M.D. Anderson Cancer Center
- Focused
We haven't built an HCP commentary report on NCT06284486 (revumenib plus venetoclax in acute myeloid leukemia with MRD) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06284486 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax; Revumenib
- Arms
- Venetoclax + Revumenib · Experimental
- Enrollment
- 8 (estimated)
- Primary outcomes
- Safety and adverse events (AEs)
- Sponsor
- M.D. Anderson Cancer Center with Syndax Pharmaceuticals, AbbVie
- Start
- Sep 23, 2024
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06284486 · updated Sep 18, 2026